---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-049317"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-04-25T23:59:59+00:00"
generated_at: "2026-06-26T05:04:34.452968+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics discontinues BDTX-189, cuts workforce 30% to extend cash runway into Q3 2024

## Summary
- Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).
- Reduced workforce by ~30% to increase operational efficiency and extend cash runway.
- Cash runway extended into Q3 2024; $209M in cash, equivalents, and investments as of Dec 31, 2021.
- Prioritized BDTX-1535 (Phase 1 for GBM/NSCLC) with clinical data update expected in 2023.
- Prioritized BDTX-4933 (BRAF inhibitor); IND submission expected in first half of 2023.

## SEC filing metadata
- accession: 0001104659-22-049317
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/0001104659-22-049317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/tm2213442d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-049317
- JSON: https://secwatch.observer/filing/0001104659-22-049317.json
- Plain text: https://secwatch.observer/filing/0001104659-22-049317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.